Quest Diagnostics Inc. (DGX)

104.85
0.03 0.03
NYSE : Health Services
Prev Close 104.88
Open 104.67
Day Low/High 104.25 / 105.10
52 Wk Low/High 78.95 / 107.97
Volume 792.22K
Avg Volume 911.20K
Exchange NYSE
Shares Outstanding 134.70M
Market Cap 14.07B
EPS 5.40
P/E Ratio 20.13
Div & Yield 2.12 (2.04%)

Monday's Health Winners & Losers

Amylin falls, while Quest Diagnostics rises.

Stock Upgrades, Downgrades From TheStreet.com Ratings

Diana Shipping upgraded; Amdocs, Centurytel, Quest Diagnostics, URS Corp. downgraded.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

3SBio, Ligand and Quest tumble on disappointing earnings reports.

Top S&P 500 Short-Squeeze Stocks

Top S&P 500 Short-Squeeze Stocks

These heavily shorted stocks could surge on good news.

Monday's Analysts' Upgrades and Downgrades

Monday's Analysts' Upgrades and Downgrades

Who made what calls.

Bullish Business Moves

Recent developments at these two names are a boon to the outlook for these stocks and the model portfolio.

Wednesday's Analysts' Upgrades and Downgrades

Who made what calls.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Wyeth loses ground after the FDA requests more data for Pristiq.

A Mutual Fund That's Kind to Animals

This value-minded Integrity offering is hoping to capitalize on the love from animal people.

Siren Song Remains the Same

Rising Treasury yields provoke another stock selloff. Barry Ritholtz, Joe Capone and Schwab's Jeff Mortimer break down the action.

Thursday's Analysts' Upgrades and Downgrades

Who made what calls.

Closeout Sale

One stock's climb primes it to be jettisoned.

Weekly Roundup

Challenges to two positions prompt reconsideration.

Trading Into the Slide

The market's retreat opens up chances to act.

A Health Care Choice

Unwinding a position in the group follows strategy.

A Firm Offer

Softer earlier, this holding has strengthened again to a level that just begs for a trade.

Weekly Roundup

The market's about to shift focus, and that requires a fresh strategy.

Cramer's 'Mad Money' Recap: Fed Stranglehold

Cramer's 'Mad Money' Recap: Fed Stranglehold

To help offset the Fed's 'intransigence,' Cramer offers his 'Three Bs' defensive portfolio.

Weekly Roundup

Now that the dust of a busy trading week has settled, find out where the portfolio stands.

Help From the Competition

Good results for a rival generate a trade in one holding.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Pharmaceutical and biotech stocks rose on M&A news.

Weekly Roundup

Find out what another record week for the markets held for the portfolio.

An Earnings Update

Here's what some portfolio members are saying about business.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Eli Lilly and MedImmune are higher.

Quest Buying AmeriPath

It will pay $1.23 billion.

Weekly Roundup

Making some strategic moves as we enter the teeth of earnings season.

Noting a Development

A rise in this holding's default swap spreads is worth monitoring. Here's why.

Weekly Roundup

Surprises in a holiday week affect the planned moves.

Weekly Roundup

Quarter-end volatility swept the market. Find out how the portfolio weathered the storm.

Dykstra: Testing LabCorp's Resilience

A customer loss earlier this month drove the stock lower, creating a good opportunity.

TheStreet Quant Rating: B (Buy)